Hong Kong Pharmaceutical Industry Association Executive Director Sabrina Chan On Competition and R&D in Hong Kong: An Interview with PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive SummaryHong Kong, with a population of just under 7 million and long known for its status as one of the most open markets in the world, can be a challenging market for pharma companies because roughly half of the drugs sold in the Special Administrative Region of China go through its Hospital Authority. It can take up to three years to get an approved product on its list of available products. The Hong Kong Pharmaceutical Industry Association, which represents 42 companies including multinational companies that operate in Hong Kong, is fighting to cut through the red tape and get innovative drugs to patients faster while trying to stay on top of a stubborn counterfeit problem, Executive Director Sabrina Chan told PharmAsia News' Hong Kong Bureau in an exclusive interview.
You may also be interested in...
Major changes are afoot in Hong Kong’s drug approval and regulatory process with safety a prime focus following a series of reforms implemented last year in response to six deaths from spurious generic drugs in 2009.